Priothera Moves Mocravimod Into Pivotal Trials
High Hopes For Leukemia Therapy
Executive Summary
The Irish biotech has launched a Phase IIb/III trial of its sphingosine 1 phosphate receptor modulator mocravimod, expanding a mode of action that has been successful in autoimmune indications into the hematology space.